
Laura Ingraham @IngrahamAngle
Why did @GileadSciences change their Remdesivir metric mid-study, from being a study to prevent death, to measuring time to recovery? In clinical studies this is a big no-no. (As discussed on #IngrahamAngle, death rate improvement was only 11.6 to 8 percent). — PolitiTweet.org